FAM
ADCT icon

Fred Alger Management’s ADC Therapeutics ADCT Stock Holding History

Fred Alger Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-125,985
Closed -$246K – 514
2023
Q1 		$246K Buy
+125,985
New +$465K ﹤0.01% 421
2020
Q4 		– Sell
-27,457
Closed -$906K – 465
2020
Q3 		$906K Sell
27,457
-7,543
-22% -$326K ﹤0.01% 350
2020
Q2 		$1.64M Buy
+35,000
New +$1.33M 0.01% 317

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fred Alger Management's ADCT Position: Q2 2023 in Review

Fred Alger Management sold out of ADC Therapeutics (ADCT) in Q2 2023, closing a stake of 125,985 shares — an estimated $246K sold.

Fred Alger Management first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $1.64M in Q2 2020. 56 funds tracked by Wall St. Rank hold ADCT as of Q2 2023.

  • Fred Alger Management reported no remaining ADC Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Fred Alger Management sold 125,985 ADC Therapeutics shares in Q2 2023, an estimated $246K.
  • Fred Alger Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
  • Fred Alger Management's ADC Therapeutics position peaked at $1.64M in Q2 2020.
  • 56 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2023.

Based on Fred Alger Management's 13F filing for Q2 2023, filed 14 Aug 2023.